234 related articles for article (PubMed ID: 9065276)
1. [Prognostic factors in patients with prostatic cancer treated with neoadjuvant hormonal therapy and radical prostatectomy].
Villavicencio Mavrich H; Chéchile Toniolo G; Salinas Duffo D; Muñoz Plaza J; Sorraca Ibáñez YJ
Arch Esp Urol; 1996 Oct; 49(8):797-806. PubMed ID: 9065276
[TBL] [Abstract][Full Text] [Related]
2. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838
[TBL] [Abstract][Full Text] [Related]
4. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Fair WR; Betancourt JE
Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant hormonal deprivation before radical prostatectomy.
Schulman CC; Sassine AM
Clin Invest Med; 1993 Dec; 16(6):523-31. PubMed ID: 7516836
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate.
Andros EA; Danesghari F; Crawford ED
Clin Invest Med; 1993 Dec; 16(6):510-5. PubMed ID: 7516835
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of neoadjuvant hormonal therapy prior to radical prostatectomy in patients with clinically localized prostate cancer: biochemical and pathological effects.
Hara I; Miyake H; Hara S; Gotoh A; Eto H; Arakawa S; Kamidono S
Hinyokika Kiyo; 2001 Jul; 47(7):453-8. PubMed ID: 11523127
[TBL] [Abstract][Full Text] [Related]
8. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
Gleave ME; Goldenberg SL; Chin JL; Warner J; Saad F; Klotz LH; Jewett M; Kassabian V; Chetner M; Dupont C; Van Rensselaer S;
J Urol; 2001 Aug; 166(2):500-6; discussion 506-7. PubMed ID: 11458055
[TBL] [Abstract][Full Text] [Related]
9. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
Zincke H; Lau W; Bergstralh E; Blute ML
J Urol; 2001 Dec; 166(6):2208-15. PubMed ID: 11696737
[TBL] [Abstract][Full Text] [Related]
10. [Neoadjuvant hormonal therapy for prostate cancer].
Miyakita H
Nihon Rinsho; 2005 Feb; 63(2):309-13. PubMed ID: 15714984
[TBL] [Abstract][Full Text] [Related]
11. [Recurrence following radical surgery for prostatic cancer. Analysis of clinical, biological and anatomo-pathological prognostic factors].
Feyaerts A; Delrée A; Lorge F; Opsomer RJ; Wese FX; Van Cangh PJ; Draguet AP; Cosyns JP
Acta Urol Belg; 1997 Mar; 65(1):11-8. PubMed ID: 9245198
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK
Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941
[TBL] [Abstract][Full Text] [Related]
13. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
[TBL] [Abstract][Full Text] [Related]
14. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial.
Labrie F; Dupont A; Cusan L; Gomez J; Diamond P; Koutsilieris M; Suburu R; Fradet Y; Lemay M; Têtu B
Clin Invest Med; 1993 Dec; 16(6):499-509. PubMed ID: 8013155
[TBL] [Abstract][Full Text] [Related]
15. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
Köllermann J; Weikert S; Schostak M; Kempkensteffen C; Kleinschmidt K; Rau T; Pantel K
J Clin Oncol; 2008 Oct; 26(30):4928-33. PubMed ID: 18794550
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up after triple treatment of prostate cancer stage pT3.
Schelin S; Madsen M; Palmqvist E; Mäkelä E; Klintenberg C; Aus G
Scand J Urol Nephrol; 2009; 43(3):186-91. PubMed ID: 19353383
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of adjuvant hormonal therapy plus radiotherapy following radical prostatectomy for patients with pT3N0 or pT3N1 prostate cancer.
Miyake H; Sakai I; Harada K; Hara I; Eto H
Int J Urol; 2004 Jun; 11(6):397-401. PubMed ID: 15157209
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant hormonal therapy in the management of prostate cancer: a surgical and radiation therapy review.
Soderdahl DW; Wettlaufer JN; Corn B; Gomella LG
Tech Urol; 1996; 2(4):194-206. PubMed ID: 9085540
[TBL] [Abstract][Full Text] [Related]
20. [Treatment results of radical prostatectomy in clinical stage B and C prostate cancer: comparison of the neoadjuvant therapy group versus the surgery group; retrospective analysis of 80 cases].
Ogura Y; Sakata Y; Wakita T; Hayashi N; Hioki T; Sugimura Y
Hinyokika Kiyo; 2003 Sep; 49(9):515-20. PubMed ID: 14598688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
